Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Hezar Jarib Ave., Isfahan, Iran.
Drug Deliv Transl Res. 2022 Oct;12(10):2261-2274. doi: 10.1007/s13346-022-01116-7. Epub 2022 Jan 11.
Understanding that cancer is one of the most important health problems, especially in advanced societies, is not difficult. The term of targeted cancer therapy has also been well known as an ideal treatment strategy in the recent years. Peptides with ability to specifically recognize the cancer cells with suitable penetration properties have been used as the targeting motif in this regard. In the present review article, we focus on an individual RGD-derived peptide with ability to recognize the integrin receptor on the cancer cell surface like its ancestor with an additional outstanding feature to penetrate to extravascular space of tumor and ability to penetrate to cancer cells unlike the original peptide. This peptide which has been named "internalizing RGD" or "iRGD" has been the focus of researches as a new targeting motif since it was discovered. To date, many types of molecules have been associated with this peptide for their targeted delivery to cancer cells. In this review article, we have discussed a summary of penetration mechanisms of iRGD and all introduced peptides and proteins attached to this attractive cell-penetrating peptide and have expressed the results of the studies.
理解癌症是最重要的健康问题之一，尤其是在发达社会，这并不难。近年来，靶向癌症治疗也已被公认为一种理想的治疗策略。具有特异性识别癌细胞并具有适当穿透特性的肽已被用作此目的的靶向结构域。在本文综述中，我们重点介绍了一种源自 RGD 的肽，它具有识别癌细胞表面整合素受体的能力，就像其前身一样，并且具有一个额外的突出特征，即能够穿透肿瘤的血管外空间，并且能够穿透癌细胞，而不像原始肽。这种肽被称为“内化 RGD”或“iRGD”，自从被发现以来，它一直是研究的焦点，作为一种新的靶向结构域。迄今为止，已经有许多类型的分子与这种肽相关联，以将其靶向递送到癌细胞。在本文综述中，我们讨论了 iRGD 的穿透机制的总结以及所有介绍的肽和蛋白质与这种有吸引力的细胞穿透肽的结合，并表达了研究结果。
